These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 31564437

  • 1. Autosomal-Recessive Mutations in MESD Cause Osteogenesis Imperfecta.
    Moosa S, Yamamoto GL, Garbes L, Keupp K, Beleza-Meireles A, Moreno CA, Valadares ER, de Sousa SB, Maia S, Saraiva J, Honjo RS, Kim CA, Cabral de Menezes H, Lausch E, Lorini PV, Lamounier A, Carniero TCB, Giunta C, Rohrbach M, Janner M, Semler O, Beleggia F, Li Y, Yigit G, Reintjes N, Altmüller J, Nürnberg P, Cavalcanti DP, Zabel B, Warman ML, Bertola DR, Wollnik B, Netzer C.
    Am J Hum Genet; 2019 Oct 03; 105(4):836-843. PubMed ID: 31564437
    [Abstract] [Full Text] [Related]

  • 2. Compound Heterozygous Frameshift Mutations in MESD Cause a Lethal Syndrome Suggestive of Osteogenesis Imperfecta Type XX.
    Stürznickel J, Jähn-Rickert K, Zustin J, Hennig F, Delsmann MM, Schoner K, Rehder H, Kreczy A, Schinke T, Amling M, Kornak U, Oheim R.
    J Bone Miner Res; 2021 Jun 03; 36(6):1077-1087. PubMed ID: 33596325
    [Abstract] [Full Text] [Related]

  • 3. Biallelic variants in MESD, which encodes a WNT-signaling-related protein, in four new families with recessively inherited osteogenesis imperfecta.
    Tran TT, Keller RB, Guillemyn B, Pepin M, Corteville JE, Khatib S, Fallah MS, Zeinali S, Malfait F, Symoens S, Coucke P, Witters P, Levtchenko E, Bagherian H, Nickerson DA, Bamshad MJ, Chong JX, University of Washington Center for Mendelian Genomics, Byers PH.
    HGG Adv; 2021 Oct 14; 2(4):100051. PubMed ID: 35047842
    [Abstract] [Full Text] [Related]

  • 4. Mutant MESD links cellular stress to type I collagen aggregation in osteogenesis imperfecta type XX.
    Ghosh DK, Udupa P, Shrikondawar AN, Bhavani GS, Shah H, Ranjan A, Girisha KM.
    Matrix Biol; 2023 Jan 14; 115():81-106. PubMed ID: 36526215
    [Abstract] [Full Text] [Related]

  • 5. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.
    Lin C, Lu W, Zhang W, Londoño-Joshi AI, Buchsbaum DJ, Bu G, Li Y.
    PLoS One; 2013 Jan 14; 8(2):e58102. PubMed ID: 23469146
    [Abstract] [Full Text] [Related]

  • 6. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
    Lu W, Liu CC, Thottassery JV, Bu G, Li Y.
    Biochemistry; 2010 Jun 08; 49(22):4635-43. PubMed ID: 20446724
    [Abstract] [Full Text] [Related]

  • 7. Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity.
    Hsieh JC, Lee L, Zhang L, Wefer S, Brown K, DeRossi C, Wines ME, Rosenquist T, Holdener BC.
    Cell; 2003 Feb 07; 112(3):355-67. PubMed ID: 12581525
    [Abstract] [Full Text] [Related]

  • 8. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
    Korvala J, Jüppner H, Mäkitie O, Sochett E, Schnabel D, Mora S, Bartels CF, Warman ML, Deraska D, Cole WG, Hartikka H, Ala-Kokko L, Männikkö M.
    BMC Med Genet; 2012 Apr 10; 13():26. PubMed ID: 22487062
    [Abstract] [Full Text] [Related]

  • 9. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
    Jacobsen CM, Barber LA, Ayturk UM, Roberts HJ, Deal LE, Schwartz MA, Weis M, Eyre D, Zurakowski D, Robling AG, Warman ML.
    J Bone Miner Res; 2014 Oct 10; 29(10):2297-306. PubMed ID: 24677211
    [Abstract] [Full Text] [Related]

  • 10. Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.
    Lin C, Lu W, Zhai L, Bethea T, Berry K, Qu Z, Waud WR, Li Y.
    FEBS Lett; 2011 Oct 03; 585(19):3120-5. PubMed ID: 21907199
    [Abstract] [Full Text] [Related]

  • 11. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP, McAlister WH, Zhang F, Bijanki VN, Nenninger A, Gottesman GS, Lin EL, Huskey M, Duan S, Dahir K, Mumm S.
    Bone; 2019 Oct 03; 127():228-243. PubMed ID: 31085352
    [Abstract] [Full Text] [Related]

  • 12. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
    Jacobsen CM, Schwartz MA, Roberts HJ, Lim KE, Spevak L, Boskey AL, Zurakowski D, Robling AG, Warman ML.
    Bone; 2016 Sep 03; 90():127-32. PubMed ID: 27297606
    [Abstract] [Full Text] [Related]

  • 13. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, Ettenberg SA, Cong F, Halleux C, Kneissel M.
    J Bone Miner Res; 2014 Jan 03; 29(1):29-42. PubMed ID: 23901037
    [Abstract] [Full Text] [Related]

  • 14. Modulation of LRP6-mediated Wnt signaling by molecular chaperone Mesd.
    Li Y, Lu W, He X, Bu G.
    FEBS Lett; 2006 Oct 02; 580(22):5423-8. PubMed ID: 16989816
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of LRP5/6-mediated Wnt/β-catenin signaling by Mesd attenuates hyperoxia-induced pulmonary hypertension in neonatal rats.
    Alapati D, Rong M, Chen S, Lin C, Li Y, Wu S.
    Pediatr Res; 2013 Jun 02; 73(6):719-25. PubMed ID: 23481549
    [Abstract] [Full Text] [Related]

  • 16. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
    Murrills RJ, Matteo JJ, Bhat BM, Coleburn VE, Allen KM, Chen W, Damagnez V, Bhat RA, Bex FJ, Bodine PV.
    J Cell Biochem; 2009 Dec 01; 108(5):1066-75. PubMed ID: 19746449
    [Abstract] [Full Text] [Related]

  • 17. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta.
    Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH.
    Am J Hum Genet; 2013 Apr 04; 92(4):590-7. PubMed ID: 23499310
    [Abstract] [Full Text] [Related]

  • 18. Lrp5 and Lrp6 play compensatory roles in mouse intestinal development.
    Zhong Z, Baker JJ, Zylstra-Diegel CR, Williams BO.
    J Cell Biochem; 2012 Jan 04; 113(1):31-8. PubMed ID: 21866564
    [Abstract] [Full Text] [Related]

  • 19. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd.
    Kubota T, Michigami T, Sakaguchi N, Kokubu C, Suzuki A, Namba N, Sakai N, Nakajima S, Imai K, Ozono K.
    J Bone Miner Res; 2008 Oct 04; 23(10):1661-71. PubMed ID: 18505367
    [Abstract] [Full Text] [Related]

  • 20. Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding.
    Li Y, Chen J, Lu W, McCormick LM, Wang J, Bu G.
    J Cell Sci; 2005 Nov 15; 118(Pt 22):5305-14. PubMed ID: 16263759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.